Merck
CN
  • Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

Effect of phylloquinone (vitamin K1) supplementation for 12 months on the indices of vitamin K status and bone health in adult patients with Crohn's disease.

The British journal of nutrition (2014-09-03)
Eibhlís M O'Connor, Geraldine Grealy, Jane McCarthy, Alan Desmond, Orla Craig, Fergus Shanahan, Kevin D Cashman
摘要

Although epidemiological findings support a role for vitamin K status in the improvement of bone indices in adult patients with Crohn's disease (CD), this needs to be confirmed in double-blind, randomised controlled trials (RCT) with phylloquinone (vitamin K1). By conducting two RCT, the present study aimed to first establish whether supplementation with 1000 μg of phylloquinone daily near-maximally suppresses the percentage of undercarboxylated osteocalcin in serum (%ucOC; marker of vitamin K status) in adult patients with CD currently in remission as it does in healthy adults and second determine the effect of supplementation with phylloquinone at this dose for 12 months on the indices of bone turnover and bone mass. The initial dose-ranging RCT was conducted in adult patients with CD (n 10 per group) using 0 (placebo), 1000 or 2000 μg of phylloquinone daily for 2 weeks. In the main RCT, the effect of placebo v. 1000 μg vitamin K/d (both co-administered with Ca (500 mg/d) and vitamin D3 (10 μg/d)) for 12 months (n 43 per group) on the biochemical indices of bone turnover (determined by enzyme immunoassay) and bone mass (determined by dual-energy X-ray absorptiometry) were investigated. At baseline, the mean %ucOC was 47 %, and this was suppressed upon supplementation with 1000 μg of phylloquinone daily ( - 81 %; P< 0·01) and not suppressed further by 2000 μg of phylloquinone daily. Compared with the placebo, supplementation with 1000 μg of phylloquinone daily for 12 months had no significant effect (P>0·1) on bone turnover markers or on the bone mass of the lumbar spine or femur, but modestly increased (P< 0·05) the bone mass of the total radius. Despite near maximal suppression of serum %ucOC, supplementation with 1000 μg of phylloquinone daily (with Ca and vitamin D3) had no effect on the indices of bone health in adult CD patients with likely vitamin K insufficiency.

材料
货号
品牌
产品描述

Supelco
胆钙化醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
胆钙化醇, ≥98% (HPLC)
Sigma-Aldrich
维生素 K 1, viscous liquid
Sigma-Aldrich
维生素 K 1, BioXtra, ≥99.0% (sum of isomers, HPLC), mixture of isomers
Supelco
维生素K1, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
胆钙化固醇(维生素 D3), analytical standard
Supelco
维生素D3标准液 CRM 溶液, 1 mg/mL in ethanol, ampule of 1 mL, certified reference material, Cerilliant®
胆钙化醇, European Pharmacopoeia (EP) Reference Standard
Supelco
叶绿醌 (K1), analytical standard
USP
胆钙化醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
胆钙化醇, meets USP testing specifications
Sigma-Aldrich
胆钙化醇, analytical standard
维生素 K 1, European Pharmacopoeia (EP) Reference Standard